Fig. 1 | Scientific Reports

Fig. 1

From: Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors

Fig. 1

Mean changes in scales during immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma. Data are expressed as means ± standard deviations. A higher score indicates a higher quality of life. Each score during treatment was compared to ‘before the initial dose of ICI (baseline, BL)’ using Wilcoxon signed-rank test (*P < 0.05, **P < 0.01, and ***P < 0.001). Dashed lines indicate the minimally important difference (MIC) for each scale. Global health status/QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (A). The functional assessment of cancer therapy-general (FACT-G) questionnaire was used to calculate total FACT-G scores (B) and social/family well-being (D). The physical component summary (PCS) was based on multi-item short form-8 questionnaire (C).

Back to article page